Whether these observed differences in the role of Phb (tumor suppressive versus oncogenic) are due to differences in TP53 and AKT mutational status, heterogeneity of the cancer cells examined [41] and/or the involvement of different Phb isoforms, are not clear and await future investigations. The gene discussed is TP53; the disease is cancer.